ATE555116T1 - Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie - Google Patents

Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie

Info

Publication number
ATE555116T1
ATE555116T1 AT09714617T AT09714617T ATE555116T1 AT E555116 T1 ATE555116 T1 AT E555116T1 AT 09714617 T AT09714617 T AT 09714617T AT 09714617 T AT09714617 T AT 09714617T AT E555116 T1 ATE555116 T1 AT E555116T1
Authority
AT
Austria
Prior art keywords
treatment
ahcy
hyperhomocysteinemia
hydrolase inhibitors
inhibitors
Prior art date
Application number
AT09714617T
Other languages
English (en)
Inventor
Robert Garbaccio
Antonella Converso
Mark Fraley
Timothy Hartingh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Application granted granted Critical
Publication of ATE555116T1 publication Critical patent/ATE555116T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
AT09714617T 2008-02-26 2009-02-18 Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie ATE555116T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6721008P 2008-02-26 2008-02-26
PCT/US2009/034344 WO2009108546A1 (en) 2008-02-26 2009-02-18 Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia

Publications (1)

Publication Number Publication Date
ATE555116T1 true ATE555116T1 (de) 2012-05-15

Family

ID=41016437

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09714617T ATE555116T1 (de) 2008-02-26 2009-02-18 Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie

Country Status (4)

Country Link
US (1) US8329697B2 (de)
EP (1) EP2257161B1 (de)
AT (1) ATE555116T1 (de)
WO (1) WO2009108546A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329697B2 (en) * 2008-02-26 2012-12-11 Merck Sharp & Dohme Corp. Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors
JP5620393B2 (ja) * 2009-10-09 2014-11-05 田辺三菱製薬株式会社 脳梗塞治療薬
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP6115962B2 (ja) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ．ベー． １−アリール−４−メチル−［１，２，４］トリアゾロ［４，３−ａ］キノキサリン誘導体
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
US10196396B2 (en) 2016-01-14 2019-02-05 Handok Inc. Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
KR102717072B1 (ko) 2017-10-18 2024-10-15 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN116840197A (zh) * 2022-03-23 2023-10-03 中国科学院苏州生物医学工程技术研究所 一种2’-o-甲基转移酶活性检测方法、试剂盒及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507294A (en) 1982-03-08 1985-03-26 Schering Corp. Imidazo[1,2-a]pyrazines
US5521162A (en) * 1987-08-26 1996-05-28 Merrell Pharmaceuticals Inc. Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions
US7208495B2 (en) 2001-07-05 2007-04-24 Takeda Pharmaceutical Company Limited Benzo-fused 5-membered hetrocycle compounds, process for preparation of the same, and use thereof
US7196093B2 (en) * 2003-04-09 2007-03-27 General Atomics Reversible inhibitors of SAH hydrolase and uses thereof
US8329697B2 (en) * 2008-02-26 2012-12-11 Merck Sharp & Dohme Corp. Imidizo[1,2-A]pyrazines useful as AHCY hydrolase inhibitors

Also Published As

Publication number Publication date
US20100305135A1 (en) 2010-12-02
EP2257161A4 (de) 2011-03-16
WO2009108546A1 (en) 2009-09-03
EP2257161B1 (de) 2012-04-25
US8329697B2 (en) 2012-12-11
EP2257161A1 (de) 2010-12-08

Similar Documents

Publication Publication Date Title
EP2257161A4 (de) Ahcy-hydrolasehemmer zur behandlung von hyperhomocysteinämie
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201170508A1 (ru) Производные 1-амино-2-циклобутилэтилбороновой кислоты
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201070247A1 (ru) Ингибиторы протеасом
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201101650A1 (ru) Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний
EA201301019A1 (ru) Бензодиоксановые ингибиторы продуцирования лейкотриена
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201270575A1 (ru) Соединения
EA200870569A1 (ru) Соединения и способы модуляции fxr
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BR112014028841A2 (pt) processo para preparação de n-[5-(3,5-difluoro-benzil)-1h-indazol-3-il]-4-(4-metil-piperazin-l-il)-2-(tetra-hidro-piran-4-ilamino)-benzamida
EA201500394A1 (ru) Ингибиторы деметилаз гистонов
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer's disease
IN2014KN02601A (de)
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
ATE506951T1 (de) Als inhibitoren von beta-secretase aktive tertiäre carbinamine mit substituierten heterocyclen zur behandlung der alzheimer- krankheit
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
EP2582676A4 (de) Positive allosterische tetrahydrochinolin-amid-m1-rezeptormodulatoren